Trypanocidal and leishmanicidal activity of six limonoids

Six limonoids [kotschyienone A and B (1, 2), 7-deacetylgedunin (3), 7-deacetyl-7-oxogedunin (4), andirobin (5) and methyl angolensate (6)] were investigated for their trypanocidal and leishmanicidal activities using bloodstream forms of Trypanosoma brucei and promastigotes of Leishmania major. Whereas all compounds showed anti-trypanosomal activity, only compounds 1–4 displayed anti-leishmanial activity. The 50% growth inhibition (GI50) values for the trypanocidal and leishmanicidal activity of the compounds ranged between 2.5 and 14.9 μM. Kotschyienone A (1) was found to be the most active compound with a minimal inhibition concentration (MIC) value of 10 μM and GI50 values between 2.5 and 2.9 μM. Only compounds 1 and 3 showed moderate cytotoxicity against HL-60 cells with MIC and GI50 values of 100 μM and 31.5–46.2 μM, respectively. Compound 1 was also found to show activity against intracellular amastigotes of L. major with a GI50 value of 1.5 μM. The results suggest that limonoids have potential as drug candidates for the development of new treatments against trypanosomiasis and leishmaniasis.


Introduction
Trypanosomiasis and leishmaniasis are devastating diseases for both humans and their domestic animals. Trypanosome parasites cause sleeping sickness in humans and nagana disease in cattle in Africa and Chagas disease in humans in Latin America [1,2]. The different Leishmania parasites cause a variety of clinical conditions (localised skin lesions, mucosal ulcers, and internal organ damage) in humans worldwide [3]. These parasites are kinetoplastid protozoans and are transmitted to their mammalian host by insect vectors. Treatment of these parasitoses relies on chemotherapy but only a few drugs are available. However, most of the drugs are not well tolerated or show toxic side effects, are not very effective, and are being increasingly subject to drug resistance. Therefore, effective and better-tolerated chemotherapies are urgently needed for the treatment of trypanosomiasis and leishmaniasis.

Electronic supplementary material
The online version of this article (https ://doi.org/10.1007/s1141 8-020-01408 -7) contains supplementary material, which is available to authorized users. Many approved drugs are based on natural compounds and their derivatives [4]. In addition, a considerable number of natural products have been shown to display potent anti-trypanosomal and anti-leishmanial activity [5]. Plants that are used in traditional medicine are promising starting materials for the discovery of natural compounds with trypanocidal and leishmanicidal activity. One such plant is Pseudocedrela kotschyi (Schweinf.) Harms (Meliaceae), which is used for the treatment of trypanosomiasis in the Kaduna state of Nigeria [6]. Furthermore, dichloromethane extracts of the roots of P. kotschyi have been shown to display anti-leishmanial activity against intracellular amastigotes of L. major [7].
In this study, we investigated the trypanocidal and leishmanicidal activity of six limonoids (Fig. 1, compounds 1-6) isolated from the roots of P. kotschyi.

In vitro toxicity assay
Toxicity assays were carried out as previously described with some modifications [17,18]. In brief, cells were seeded in 96-well plates in a final volume of 200 μL of appropriate medium containing various concentrations of test compounds (tenfold dilution from 100 µM to 1 nM) and 1% DMSO. Wells just containing medium and 1% DMSO served as controls. The initial cell densities were 1 × 10 4 /mL for T. brucei bloodstream forms, 2.5 × 10 5 /mL for L. major promastigotes, and 5 × 10 4 /mL for HL-60 cells. After 24 h incubation, 20 µL of a 0.5 mM resazurin solution prepared in PBS was added and the cells were incubated for a further 48 h. Thereafter, the absorbance of wells was read on a BioTek ELx808 microplate reader using a test wavelength of 570 nm and a reference wavelength of 630 nm. The 50% growth inhibition (GI 50 ) value, i.e., the concentration of a compound necessary to reduce the growth rate of cells by 50% compared to the control, was determined by linear interpolation [19]. The minimum inhibitory concentration (MIC) values, i.e. the concentration of a compound at which all trypanosomes and human cells were killed, was determined microscopically.

Intra-macrophages amastigote assay
The intra-macrophages amastigote assay was performed as previously described with some modification [20]. In brief,

Results and discussion
All six limonoids 1-6 showed a dose-dependent inhibitory effect on the growth of bloodstream forms of T. brucei with MIC values ranging from 10 to > 100 μM and GI 50 values ranging from 2.48 to 14.5 μM (Table 1). Similar activities were also observed with promastigotes of L. major for the four gedunin-type limonoids 1-4 (Table 1). In contrast to their trypanocidal activity, the two andirobin-type limonoids 5 and 6 displayed no leishmanicidal activity (MIC and GI 50 > 100 μM, Table 1). The most active compound against both parasites was 1 with a MIC value of 10 μM and GI 50 value of 2-3 μM (Table 1). On the other hand, only compounds 1 and 3 showed some cytotoxic activity against human HL-60 cells with MIC values of 100 μM and GI 50 values in the mid micromolar range ( Table 1). The other four compounds (2, 4, 5 and 6) displayed no cytotoxicity against HL-60 cells (MIC and GI 50 > 100 μM, Table 1). Based on the antiparasitic and cytotoxic activities, only the gedunintype limonoid 1 exhibited moderated selectivity indices with MIC and GI 50 ratios of ≥ 10 ( Table 2). Compared with suramin and amphotericin B, two drugs used in the treatment of sleeping sickness and cutaneous leishmaniasis, respectively, the six limonoids were 10-1000 times less active ( Table 1). The higher antiparasitic activity of the drugs is also reflected in their greater selectivity indices of at least > 100 ( Table 2).
As compound 1 was found to be the most potent leishmanicidal limonoid, we investigated its ability to kill L. major amastigotes within macrophages. The compound was able to reduce the parasite burden of infected macrophages with an ED 50 (50% effective dose) of 1.51 μM (Fig. 2). Thus, compound 1 was almost twice as effective in affecting intracellular amastigotes than extracellular promastigotes (GI 50(promastigotes) = 2.86 μM vs ED 50(amastigotes) = 1.51 μM). At 10 μM, compound 1 killed completely intracellular amastigotes and only vacuoles containing fragments of parasites could be seen (Supplementary Figure S7). However, compared with amphotericin B, compound 1 was less potent in killing amastigotes within macrophages. The licensed drug was able to completely destroy intracellular amastigotes at a concentration of 0.1 μM (Fig. 2).
The trypanocidal and leishmanicidal activity of compounds 1-6 are in good agreement with previously reported antiprotozoal activities. For instance, the GI 50 values for their anti-plasmodial activity were found to be within the range of 1.7-19.3 μM [8]. Compounds 3 and 4 have been previously reported to inhibit the growth of bloodstream forms of T. brucei rhodesiense with GI 50 values of 3.4 μM [21]. Axenic grown amastigotes of L. donovani were affected by 3 and 4 with GI 50 values of around 1 μM [21]. These activities are somewhat lower than those we found for 3 and 4 with promastigotes of L. major. The observed differences may be due to that axenic grown amastigotes are more sensitive as they are removed from their natural environment of a host cell.
Structure-activity relationship analysis revealed that the presence of a hydroxyl group at the C-7 position reduces the activity of the gedunin-type limonoids. For example, compound 2 with a hydroxyl group at C-7 displayed 5-6  times lower trypanocidal and leishmanicidal activity than compound 1 with a hydrogen atom at the position ( Fig. 1 and Table 1). Likewise, compound 4 is 1.5-4.6 times less active than compound 3 which has a keto functional group instead of a hydroxyl group at the C-7 position ( Fig. 1 and Table 1). These findings indicate that a slight increase in hydrophilicity reduces the trypanocidal and leishmanicidal activity of the gedunin-type limonoids. This study has shown that phytochemical investigation of plants utilised in traditional medicine can yield the identification of compounds apparently responsible for the activity ascribed to their indigenous use. Here it was revealed that six limonoids isolated form the roots of P. kotschyi, a plant used for treating trypanosomiasis in domestic animals in Nigeria [6], display anti-trypanosomal activity. Kotschyienone A (1) was found to be not only the most active compound against T. brucei but also against L. major. Whereas compound 1 did not fully match the GI 50 activity criteria for drug candidates for African trypanosomiasis [< 0.2 μg/ mL vs 1.09 μg/mL (2.48 μM)], it fulfilled the GI 50 activity criteria for drug candidates for leishmaniasis [< 1 μg/mL vs 0.66 μg/mL (1.51 μM)] [22]. The moderate selectivity indices of compound 1 did not correspond with selectivity index activity criteria for both parasite species (Trypanosoma > 100; Leishmania > 20 [22]). However, it should be pointed out that in this study a cancer cell line was used for determining selectivity and that, compared with non-malignant cells, the cytotoxicity of compound 1 may, therefore, be overestimated. For example, the cytotoxicity of 1 for the immortalised human embryonic kidney cell line HEK239T was previously determined to be > 200 μg/mL [8]. Based on this cytotoxicity, compound 1 would match the selectivity index activity criteria for drug candidates for both bloodstream forms of T. brucei and intracellular amastigotes of L. major. In conclusion, the gedunin-type limonoids seem to be a promising class of compounds for further anti-trypanosomal and anti-leishmanial drug development.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.